0707基因杂质PhRMA文献综述Word下载.docx
- 文档编号:4380184
- 上传时间:2023-05-03
- 格式:DOCX
- 页数:16
- 大小:55.55KB
0707基因杂质PhRMA文献综述Word下载.docx
《0707基因杂质PhRMA文献综述Word下载.docx》由会员分享,可在线阅读,更多相关《0707基因杂质PhRMA文献综述Word下载.docx(16页珍藏版)》请在冰点文库上搜索。
23
Average:
5
Yourrating:
NoneAverage:
5(1vote)
Author(s):
poonmphar
Decisionstoapprove,prescribeandconsumemedicinesinvolverisk/benefitassessmentsbyregulatoryagencies,healthcareprofessionalsandconsumers.Forseriousorlifethreateningconditions,drugswithhigherrisksforadverseeffectsorforseriousadverseeffectsaresometimesacceptable.Forexample,somelife-savingcancerchemotherapiesareknownhumancarcinogens.However,ifoneissufferingfromalifethreateningtumor,a5%riskofasecondary,treatment-relatedtumorisgenerallyconsideredacceptable.Arguably,thesameisnottrueforimpuritiesfoundindrugsubstancesanddrugproducts;
impuritiesconveyonlyriskwithnoassociatedbenefit.Drugimpuritiesmightbeviewedas“pollutants”inthepharmaceuticalworld.Muchlikepollutantsintheenvironment,fewpeoplebelievethattheycanbeentirelyeliminated.Thechallengeforregulatoryagenciesistopromulgatestandardsthatassurethatunavoidabledrugimpuritiesimpartnooracceptablelevelsofrisk.
Residualimpuritiesresultingfrommanufacturingandformulation,orfromdegradationoftheactivepharmaceuticalingredient(API)andexcipients,maybepresentinpharmaceuticalproducts.Asubsetoftheseimpuritiesmaypresentapotentialforgenotoxicityandthereforeposeanadditionalsafetyconcerntoclinicalsubjectsandpatients.Thepharmaceuticalindustryandthosethatregulateitrecognizetheirrespectiveobligationtolimitgenotoxicimpurities.Therefore,substantialeffortsaremadeduringdevelopmenttocontrolallimpuritiesatsafeconcentrations.However,theeffortmadetolimitimpuritiesmustbecommensuratewiththeriskassessedateachphaseofclinicaldevelopment,takingintoaccounttheextentofthehazard,thediseaseindication,thesizeandcharacteristicsoftheexposedpopulation,andthedurationofthatexposure,aswellasthelikelydelayintheavailabilityofbeneficialmedicinesiftheburdenoflimitingorcontrollingimpuritylevelsisdisproportionate.Abalanceoftheseconsiderationscanbedescribedbestasthe‘‘aslowasreasonablypracticable’’(ALARP)principle.Itfollowsthatthepresenceofimpuritieswithgenotoxic(mutagenic)potentialmaybeunavoidableinclinicaltrialandultimatelyinapprovedandmarketedmaterials.ControlofimpuritiesinthedrugsubstanceanddegradantsindrugproductareaddressedinICHQualityGuidelinesQ3A(R)andQ3B(R),respectively,andtheQ3Cguidelinethatdealswithresidualsolvents.However,nospecificguidancefordeterminingacceptablelevelsforgenotoxicimpuritiesisprovidedinthesedocumentsotherthantorecognizethefactthatunusuallytoxicimpuritiesmayrequiretighterlimitsofcontrol.
LimitingGenotoxicImpurities:
Amajorchangeinimpuritytestinginvolvesanewregulatoryguidancedesignedtotightlylimitsubstancespossessingpotentialforgenotoxicity.TheEuropeanAgencyfortheEvaluationofMedicinalProducts(EMEA)guidanceongenotoxicimpurities,whichbecameeffectiveonJan.1,2007,nowappliesa1.5μgdailyexposurelimitforsuchsubstancesinmostpharmaceuticalsbasedonaprecedentapplicationofthethresholdoftoxicologicalconcern(TTC)concepttofoodadditivesandfoodcontactmaterials.BeforetheEMEAdraftguidance,genotoxicimpuritieshadbeenaddressedonlyasafootnoteinICHQ3A(R2)"
ImpuritiesinNewDrugSubstances"
.
In2004,thePharmaceuticalResearchandManufacturersofAmerica(PhRMA)formedataskforcetodiscussgenotoxicimpuritylimits.Concernedthe1.5μg/daylimitwouldbeappliedtodrugssynthesizedintheUnitedStates,evenwhilethesedrugswerestillinclinicaldevelopment,thePhRMAgroupproposedastagedTTCapproachthattiespermissibleimpuritylevelstothestageofdevelopment.Becauseclinicalstudiesareconductedwithlimiteddurationofdosing,thegroupreasonedthattotalexposureisverylow,andthushigherintakelevelsshouldbeallowableduringearlyclinicalstudieswithoutanetincreaseinrisk.PhRMA'
sstagedTTCapproachappliestoallclinicalroutesandtocompoundsatallstagesofdevelopment,foridentifiedandpredictedimpurities.TheTTClimitswouldnotapplytoalreadymarketedproducts.
USFDAhasconsideredboththeguidelinesinsettinglimitsongenotoxicimpurities.
EmeaGuidelineOnLimitsOfGenotoxicImpurities
TheEuropeanMedicinesAgency'
s(EMEA)CommitteeforMedicinalProductsforHumanUse(CHMP)publishedaguidelineonthelimitsofgenotoxicimpurities.Thisguidelinerecommendsdichotomizinggenotoxicimpuritiesintothoseforwhichthereis“sufficient(experimental)evidenceforathreshold-relatedmechanism”andthose“withoutsufficient(experimental)evidenceforathreshold-relatedmechanism.
”ThosegenotoxiccompoundswithsufficientevidencewouldberegulatedusingmethodsoutlinedinICHQ3C,forclass2solvents.Thisapproachcalculatesa“permitteddailyexposure”(PDE)whichiscalculatedusingtheNOELorLOELfromthemostrelevantanimalstudyplusincorporationofsafetyfactors.Examplesofgenotoxinsthatmayfallintothisclassincludechemicalsthatinduceaneuploidybyinterferingwiththemitoticspindle,chemicalsinterferingwithactivityoftopoisomeraseorchemicalsthatinhibitDNAsynthesis.
Forgenotoxiccompoundswithoutsufficientevidenceforathreshold-relatedmechanism,theguidelineproposesapolicyofcontrollinglevelsto“aslowasreasonablypracticable”(ALARPprincipal).Thisapproachspecifiesthateveryeffortshouldbemadetopreventtheformationofsuchcompoundsduringdrugsubstancesynthesisand,ifnotpossible,effortsshouldbemadetoreducesuchimpuritiesthroughtechnicalefforts(e.g.purificationsteps).CompoundsfallingintothisclassaregenerallythosethatinteractwithDNAeitherdirectlyorindirectlysuchasalkylatingagents,intercalatingagentsoragentsgeneratingfreeradicals.Sinceallexposurestosuchagentstheoreticallyconveysomelevelofcarcinogenicrisk,regulatoryagenciesgenerallyperformquantitativeriskassessmentstocalculatetheincreasedlevelsofadverseevents,suchascancers,thatresultfromparticularexposuresandsetexposurelevelswhichresultin“acceptable”risks;
often1in105or1in106additionalcancersfromlifetimeexposures.
Whiletheapproachdescribedabovehassoundscientificsupport,inmostinstancessufficientmechanisticdatawillbelackingwithwhichtodecidewhetherathresholdmechanismisapplicableforgenotoxicimpurities.Furthermore,itisalsounlikelythatdatawillexistonwhichquantitativeriskassessmentscanbeperformed.Theguidelinerecognizestheselimitationsandthereforeproposestheuseofa“thresholdoftoxicologicalconcern”(TTC)forgenotoxicimpurities.TheTTCreferstoathresholdexposureleveltocompoundsthatwillnotposeasignificantriskofcarcinogenicityorothertoxiceffectsandwasoriginallydevelopedasa“thresholdofregulation”forfoodcontactmaterialsbytheFDA.ThedraftguidelineproposesaTTCof1.5µ
g/day.Thisthresholdcorrespondstoa10-5lifetimeriskofcancer,arisklevelthattheEMEAconsidersjustifiedduetothebenefitsderivedfrompharmaceuticals.Importantly,however,thisdraftguidelineonlyaddresseslevelsofgenotoxicimpuritiesinmarketedproducts;
theguidelineissilentonwhatmightconstituteacceptableTTCsfordrugsduringdevelopment,especiallyfortrialsofshortduration.
1-GenotoxicCompoundswithSufficientEvidenceforaThreshold-RelatedMechanism
Examplesofmechanismsofgenotoxicitythatmaybedemonstratedtoleadtonon-linearorthresholdeddose-responserelationshipsincludeinteractionwiththespindleapparatusofcelldivisionleadingtoaneuploidy,topoisomeraseinhibition,inhibitionofDNAsynthesis,overloadingofdefencemechanisms,metabolicoverloadandphysiologicalperturbations(e.g.inductionoferythropoeisis,hyper-orhypothermia).For(classesof)compoundswithclearevidenceforathresholdedgenotoxicity,exposurelevelswhicharewithoutappreciableriskofgenotoxicitycanbeestablishedaccordingtotheprocedureasoutlinedforclass2solventsintheQ3CNoteforGuidanceonImpurities:
ResidualSolvents.Thisapproachcalculatesa“PermittedDailyExposure”(PDE),whichisderivedfromtheNOEL,orthelowestobservedeffectlevel(LOEL)inthemostrelevant(animal)studyusing“uncertaintyfactors”(UF).
2-GenotoxicCompoundswithoutSufficientEvidenceforaThreshold-Related
Mechanism
Theassessmentofacceptabilityofgenotoxicimpuritiesforwhichnothresholdmechanismsareidentifiedshouldincludebothpharmaceuticalandtoxicologicalevaluations.Ingeneral,pharmaceuticalmeasurementsshouldbeguidedbyapolicyofcontrollinglevelsto“aslowasreasonablypracticable”(ALARPprinciple),whereavoidingisnotpossible.LevelsconsideredbeingconsistentwiththeALARPprinciplefollowingpharmaceuticalassessmentshouldbeassessedforacceptabilityfromatoxicologicalpointofview.
2.1PharmaceuticalAssessment
Arationaleoftheproposedformulation/manufacturingstrategyshouldbeprovidedbasedonavailableformulationoptionsandtechnologies.Theapplicantshouldhighlight,withinthechemicalprocessandimpurityprofileofactivesubstance,allchemicalsubstances,usedasreagentsorpresentasintermediates,orside-products,knownasgenotoxicand/orcarcinogenic(e.g.alkylatingagents).Moregenerally,reactingsubstancesandsubstanceswhichshow“alertingstructure”intermsofgenotoxicitywhicharenotsharedwiththeactivesubstanceshouldbeconsidered.Potentialalternativeswhichdonotleadtogenotoxi
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 0707 基因 杂质 PhRMA 文献 综述
![提示](https://static.bingdoc.com/images/bang_tan.gif)